Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?

Rheumatology (United Kingdom)

Volumn 53, Issue 6, 2014, Pages 1108-1119

  Tam, Lai Shan ^a   Kitas, George D ^b   Gonźlez gay, Miguel A ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Rheumatology Service Hospital Universitario Marqús de Valdecilla IFIMAV   (Spain)

Author keywords

Ankylosing spondylitis; Arterial stiffness; Augmentation index; Intima media thickness; Psoriatic arthritis; Pulse wave velocity; Rheumatoid arthritis; TNF antagonists

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKLE BRACHIAL INDEX; ANKYLOSING SPONDYLITIS; AORTIC AUGMENTATION INDEX; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUGMENTATION INDEX; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFECT; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; LONG TERM CARE; MONOTHERAPY; NON INVASIVE MEASUREMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS; ATHEROSCLEROSIS; BIOLOGICAL PRODUCTS; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; HUMANS; PULSE WAVE ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 84900824198     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket454     Document Type: Article

References (102)

1. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
2. Avina-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
3. Avina-Zubieta JA, Thomas J, Sadatsafavi M et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
4. Goodson NJ, Wiles NJ, Lunt M et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46:2010-9.
5. Young A, Koduri G, Batley M et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007;46:350-7.
6. Kremers HM, Crowson CS, Therneau TM et al. High tenyear risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008;58:2268-74.
7. Mok CC, Kwok CL, Ho LY et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011;63:1182-9.
8. Wong K, Gladman DD, Husted J et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40: 1868-72.
9. Ali Y, Tom BD, Schentag CT et al. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007; 56:2708-14.
10. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270: 147-57.
11. Buckley C, Cavill C, Taylor G et al. Mortality in psoriatic arthritis-a single-center study from the UK. J Rheumatol 2010;37:2141-4.
12. Shbeeb M, Uramoto KM, Gibson LE et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.
13. Gladman DD, Ang M, Su L et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.
14. Han C, Robinson DW Jr, Hackett MV et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
15. Gladman DD, Farewell VT, Wong K et al. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998; 41:1103-10.
16. Tam LS, Tomlinson B, Chu TT et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology 2008; 47:718-23.
17. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
18. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5.
19. Mathieu S, Gossec L, Dougados M et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res 2011;63:557-63.
20. Peters MJ, Visman I, Nielen MM et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
21. Brophy S, Cooksey R, Atkinson M et al. No increased rate of acute myocardial infarction or stroke among patients with ankylosing spondylitis-a retrospective cohort study using routine data. Semin Arthritis Rheum 2012;42: 140-5.
22. Bremander A, Petersson IF, Bergman S et al. Populationbased estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011;63:550-6.
23. Szabo SM, Levy AR, Rao SR et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294-304.
24. Kang J-H, Chen Y-H, Lin H-C. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population- based study. Ann Rheum Dis 2010;69:1165-8.
25. Nichols WW, Pepine CJ, O'Rourke MF. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke. N Engl J Med 1999;340: 1762-3.
26. Gonzalez-Juanatey C, Llorca J, Martin J et al. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:366-71.
27. Evans MR, Escalante A, Battafarano DF et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011;63: 1211-20.
28. Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96: 1432-7.
29. Sabetai MM, Tegos TJ, Nicolaides AN et al. Reproducibility of computer-quantified carotid plaque echogenicity: can we overcome the subjectivity? Stroke 2000;31:2189-96.
30. Polak JF, Szklo M, Kronmal RA et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2013;2:e000087. doi: 10.1161/JAHA.113.000087.
31. Corrales A, Gonzalez-Juanatey C, Peiro ME et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2013 Mar 16 [Epub ahead of print].
32. Tam LS, Shang Q, Li EK et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59:1322-31.
33. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27: 2588-605.
34. Van Bortel LM, Laurent S, Boutouyrie P et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445-8.
35. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
36. Tanaka H, Munakata M, Kawano Y et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009;27:2022-7.
37. Wilkinson IB, Hall IR, MacCallum H et al. Pulse-wave analysis. Arterioscler Thromb Vasc Biol 2002;22:147-52.
38. Mackenzie IS, Wilkinson IB, Cockcroft JR. Assessment of arterial stiffness in clinical practice. QJM 2002;95:67-74.
39. Vlachopoulos C, Aznaouridis K, O'Rourke MF et al. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1865-71.
40. van Sijl AM, Peters MJ, Knol DK et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011;40: 389-97.
41. Stamatelopoulos KS, Kitas GD, Papamichael CM et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009; 29:1702-8.
42. Protogerou A, Zampeli E, Tentolouris N et al. Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study. Ann Rheum Dis 2012;71:1534-6.
43. Maki-Petaja KM, Hall FC, Booth AD et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factoralpha therapy. Circulation 2006;114:1185-92.
44. Klocke R, Cockcroft JR, Taylor GJ et al. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis 2003;62: 414-8.
45. Avalos I, Chung CP, Oeser A et al. Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. J Rheumatol 2007;34: 2388-94.
46. Wallberg-Jonsson S, Caidahl K, Klintland N et al. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol 2008;37:1-5.
47. Provan SA, Angel K, Semb AG et al. Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis. J Rheumatol 2011;38: 606-12.
48. Pieringer H, Schumacher S, Stuby U et al. Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin Arthritis Rheum 2009;39:163-9.
49. Hannawi S, Haluska B, Marwick T et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007;9: R116.
50. Georgiadis AN, Voulgari PV, Argyropoulou MI et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008;38:13-9.
51. El-Barbary AM, Kassem EM, El-Sergany MAS et al. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. J Rheumatol 2011;38:828-34.
52. Ahmed H, Youssef M, Mosaad Y. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol 2010;29:1237-43.
53. Turiel M, Atzeni F, Tomasoni L et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology 2009;48:834-9.
54. Sodergren A, Karp K, Boman K et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010;12:R158.
55. Yildiz M, Soy M, Kurum T et al. Increased pulse wave velocity and shortened pulse wave propagation time in young patients with rheumatoid arthritis. Can J Cardiol 2004;20:1097-100.
56. Eder L, Zisman D, Barzilai M et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008;35:877-82.
57. Kimhi O, Caspi D, Bornstein NM et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
58. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-80.
59. Hamdi W, Chelli Bouaziz M, Zouch I et al. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2012;39:322-6.
60. Bodnar N, Kerekes G, Seres I et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011;38:723-9.
61. Moyssakis I, Gialafos E, Vassiliou VA et al. Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. Scand J Rheumatol 2009;38: 216-21.
62. Peters MJL, van Eijk IC, Smulders YM et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37:161-6.
63. Demiralp E, Kardesoglu E, Kiralp MZ et al. Aortic elasticity in patients with ankylosing spondylitis. Acta Cardiol 2004; 59:630-4.
64. Capkin E, Kiris A, Karkucak M et al. Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2011;78:378-82.
65. Mathieu S, Joly H, Baron G et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008;47:1203-7.
66. Choe JY, Lee MY, Rheem I et al. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008;75:548-53.
67. Malesci D, Niglio A, Mennillo GA et al. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007;26:710-4.
68. Gonzalez-Juanatey CM, Vazquez-Rodriguez TR, Miranda- Filloy JA et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009; 88:358-65.
69. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011;70:8-14.
70. van Kuijk AW, Reinders-Blankert P, Smeets TJ et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65: 1551-7.
71. Dixon WG, Symmons DPM. What effects might anti-TNFa treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFa in cardiovascular pathophysiology. Ann Rheum Dis 2007;66:1132-6.
72. Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011;63:522-9.
73. Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ. Effects of biologic agents and other disease- modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des 2013 Apr 2 [Epub ahead of print].
74. Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011;50:518-31.
75. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C et al. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006;55:150-3.
76. Sidiropoulos PI, Siakka P, Pagonidis K et al. Sustained improvement of vascular endothelial function during anti- TNF alpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009;38:6-10.
77. Wong M, Oakley SP, Young L et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1277-84.
78. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda- Filloy JA et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm 2012;2012: 674265.
79. Del Porto F, Lagana B, Lai S et al. Response to antitumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007;46: 1111-5.
80. Ferrante A, Giardina A, Ciccia F et al. Long-term antitumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis. Rheumatol Int 2009;30:193-8.
81. Kerekes G, Soltesz P, Szucs G et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 2011;13:147-52.
82. Angel K, Provan SA, Fagerhol MK et al. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644-50.
83. Tam LS, Li EK, Shang Q et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 2011;70:705-6.
84. Van Sijl AM, van Eijk IC, Peters MJ et al. Tumor necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis 2013, doi: 10.1136/annrheumdis-2013- 203934.
85. Tam LS, Shang Q, Li EK et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis-a randomized trial. J Rheumatol 2012;39:2267-75.
86. Kume K, Amano K, Yamada S et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011;38:2169-71.
87. Tam LS, Shang Q, Kun EW et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis-a randomized, placebo-controlled pilot trial. Rheumatology 2014;53:doi: 10.1093/rheumatology/ ket469.
88. Cypiene A, Laucevicius A, Venalis A et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc 2007;50: 119-22.
89. Mäki-Petäjä KM, Elkhawad M, Cheriyan J et al. Anti-tumor necrosis factor-a therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473-80.
90. Komai N, Morita Y, Sakuta T et al. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod Rheumatol 2007;17: 385-90.
91. Daïen CI, Fesler P, du Cailar G et al. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:881-7.
92. Capkin E, Karkucak M, Kiris A et al. Anti-TNF-a therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology 2012;51:910-4.
93. Mathieu S, Pereira B, Couderc M et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology 2013;52: 204-9.
94. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005;44:1428-32.
95. Galarraga B, Khan F, Kumar P et al. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology 2009;48:1418-23.
96. Pieringer H, Stuby U, Pohanka E et al. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin Rheumatol 2010; 29:723-7.
97. Baraliakos X, Listing J, Haibel H et al. Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol 2013;40:1891-6.
98. Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS et al. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology 2011;50: 2125-39.
99. O'Dell JR, Mikuls TR, Taylor TH et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18.
100. van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2013;374: 459-66.
101. Moreland LW, O'Dell JR, Paulus HE et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 2012;64:2824-35.
102. Guin A, Chatterjee Adhikari M et al. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 2013;43:48-54.